1. Home
  2. PULM

as 05-30-2025 4:00pm EST

$
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).

Founded: 2003 Country:
United States
United States
Employees: 2 City: FRAMINGHAM
Market Cap: 28.3M IPO Year: N/A
Target Price: N/A AVG Volume (30 days): 20.6K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -3.35 EPS Growth: N/A
52 Week Low/High: $1.78 - $10.40 Next Earning Date: 05-15-2025
Revenue: $1,921,000 Revenue Growth: -83.56%
Revenue Growth (this year): -8.47% Revenue Growth (next year): 134.88%

PULM Daily Stock ML Predictions

Share on Social Networks: